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Diagnosis and management of antiretroviral-therapy failure 
in resource-limited settings in sub-Saharan Africa: challenges 
and perspectives
Anthony D Harries, Rony Zachariah, Joep J van Oosterhout, Steven D Reid, Mina C Hosseinipour, Vic Arendt, Zengani Chirwa, Andreas Jahn, 
Erik J Schouten, Kelita Kamoto
Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many 
challenges remain, not least of which are the identiﬁ  cation and management of patients who have failed ﬁ  rst-line 
therapy. Less than 3% of patients are receiving second-line treatment at present, whereas 15–25% of patients have 
detectable viral loads 12 months or more into treatment, of whom a substantial proportion might have virological 
failure. We discuss the reasons why virological ART failure is likely to be under-diagnosed in the routine health 
system, and address the current diﬃ   culties with standard recommended second-line ART regimens. The development 
of new diagnostic tools for ART failure, in particular a point-of-care HIV viral-load test, combined with simple and 
inexpensive second-line therapy, such as boosted protease-inhibitor monotherapy, could revolutionise the management 
of ART failure in resource-limited settings. 
Introduction
“This is not the end. It is not even the beginning of the 
end. But it is perhaps, the end of the beginning.”
Sir Winston Churchill, 1942, 
speech at the Mansion House, London, 
referring to the Battle of Egypt
The scale-up of antiretroviral therapy (ART) in low-income 
and middle-income countries has been unprecedented, 
with more than 4 million people in such countries 
estimated to have access to ART at the end of 2008.
1 Hope 
and optimism have slowly but steadily begun to replace 
despair and death in those countries and areas most 
aﬀ  ected by the HIV/AIDS epidemic. However, challenges 
remain, particularly in resource-limited settings. Too few 
people are still receiving treatment, too many patients 
start treatment late, and the present ﬁ  rst-line  ART 
armamentarium is too toxic. One major challenge that is 
increasingly beginning to confront established HIV care 
programmes is what to do about ART failure and second-
line treatment. 
The aim of this Personal View is to review the current 
diﬃ   culties with diagnosing and managing ART failure in 
resource-limited settings in sub-Saharan Africa, and to 
expound the rationale and arguments for the development 
of a point-of-care (POC) viral-load test and second-line 
treatment based on protease-inhibitor monotherapy. We 
think that this package is feasible for decentralised care 
and will facilitate better quality HIV care than is the case 
at present. 
ART in Africa and low use of second-line regimens
The increased use of ART in sub-Saharan Africa has been 
a success story for the region. In 2003, about 2% of patients 
in need of treatment received ART. By the end of 2008, the 
region had increased this coverage to 44%, with 2·9 million 
patients estimated to be receiving this life-saving 
medication.
1 Malawi, a poor, land-locked country in 
southern Africa, with an annual gross domestic product of 
less than US$200 per person and a population of 
13 million,
2 is one of those countries that has done well. In 
2003, only a few sites were delivering ART to patients, 
there were no standardised systems to track cases or 
outcomes, and patients had to pay for their medication. By 
the end of December, 2008, over 196 000 new patients had 
started on ART, which is oﬀ  ered free of charge in the 
public sector and at a subsidised rate in the private sector 
(table 1).
3 
In a WHO survey involving national AIDS programmes 
in countries with a high burden of HIV in 2008, about 
98% of patients who had been started on ART were on 
ﬁ  rst-line regimens, the most common being stavudine, 
lamivudine, and nevirapine.
1 The same survey reported 
that only 2% of adults and 3% of children were on second-
line ART, the usual regimens being based on nucleoside 
reverse transcriptase inhibitors (NRTIs) and a protease 
inhibitor, which was invariably ritonavir-boosted lopinavir.
1 
However, countries vary in reported use of second-line 
ART. In South African children, the cumulative probability 
of switching to second-line ART was 6% at 3 years,
4 
whereas in the resource-poor environment of Malawi, 
which has good national recording and reporting systems, 
only 518 (0·3%) of the 145  479 patients known to be alive 
and on ART by December, 2008, had been switched to a 
second-line regimen.
3 
There are various explanations for low use of second-
line ART, but one of the most important is the inability to 
identify and diagnose patients who have failed ﬁ  rst-line 
therapy. In high-income countries, the diagnosis of ART 
failure is based on measurements of HIV RNA 
concentration. For example, in the UK and USA, a plasma 
HIV RNA concentration of above 50 copies per mL on two 
consecutive occasions is used to deﬁ  ne virological failure.
5,6 
In a study of ART in 14 African countries, Akileswaran and 
colleagues
7 found that 27% of patients who had been on 
ART for 6 months to 4 years had plasma HIV RNA 
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concentrations greater than 500 copies per mL. Similarly, 
in a study of 18 ART clinics, 13 of which were in sub-
Saharan Africa, 24% of patients had plasma HIV RNA 
concentrations greater than 500 copies per mL at 
6 months.






13 showed that 
15–25% of patients had plasma HIV RNA concentrations 
greater than 400 copies per mL at 6–36 months after 
starting ﬁ  rst-line ART. Cross-sectional studies often fail to 
diﬀ  erentiate true virological failure from detectable viral 
loads due to viral “blips” (occasional increases in viraemia 
during otherwise successful HIV suppression) or poor 
adherence. In a cohort study from South Africa, an HIV 
RNA concentration above 1000 copies per mL was noted 
in 7% of patients, but after use of targeted adherence 
interventions by peer counsellors, virological failure 
(deﬁ  ned as HIV RNA greater than 1000 copies per mL on 
two consecutive occasions) was only conﬁ  rmed in 2%.
14 
Important risk factors for the development of drug 
resistance, particularly in sub-Saharan Africa, include 
intermittent interruptions of treatment due to drug 
unavailability (so-called “stock outs”) or side-eﬀ  ects, use of 
nevirapine-based ART after single-dose nevirapine has 
been used to prevent perinatal HIV transmission,
15,16 and 
inadequate nevirapine concentrations resulting from the 
interaction with rifampicin.
17 A recent systematic review 
and meta-analysis showed that there might be high levels 
of genotypic resistance to NRTIs in resource-poor settings, 
particularly if viral-load monitoring is not available.
18 In 
Malawi, among patients starting second-line ART in the 
public programme, 95% had at least one major drug 
mutation, 93% had dual-class resistance, and 17% of 
patients had resistance to all available NRTIs.
19
Management in routine settings
The main reason for not detecting virological ART failure 
is lack of resources. Table 2 summarises the diﬀ  erences in 
gross domestic product, health expenditures, skilled 
human resources, and HIV burden between the UK and 
Malawi.
2,3,5,20,21 These disparities explain the way in which 
ART is managed in the two countries. In brief, the 
management of patients with HIV in the UK is guided by 
regular and reliable laboratory monitoring such as CD4-
lymphocyte count, plasma HIV RNA concentration, and 
drug-resistance proﬁ   les, with sophisticated technology 
being used to determine whether certain ﬁ  rst, second, or 
third-line drugs are contraindicated (ie, the presence of 
HLA-B*5701 indicates high risk of hypersensitivity to 
abacavir) or can be used (ie, viral tropism assays for 
maraviroc). 
The management of ART in a resource-poor country 
such as Malawi could not be more diﬀ  erent. Patients are 
eligible for ART if they are conﬁ  rmed as being infected 
with HIV, the patient or guardian understands the 
implications of ART and life-long therapy, and the patient 
is assessed as being in WHO clinical stage 3 or 4 or has a 
CD4-cell count below the threshold for severe immuno-
deﬁ   ciency, which in the case of adults is below 
250×10⁶ cells per L.
22,23 In Malawi, about 75% of the ART 
clinics have no facility to measure CD4-cell counts, and the 
emphasis is therefore on WHO clinical staging. If eligible 
for ART, patients go through a process of group and 
individual counselling before starting treatment. First-line 
ART regimen is a standardised generic, ﬁ  xed-dose 
combination treatment with stavudine, lamivudine, and 
nevirapine. All patients starting ﬁ  rst-line ART are seen 
2 weeks after treatment initiation and then every 4 weeks 
for the ﬁ  rst 6 months. Stable patients are then followed up 
at 2-monthly intervals for life. Monitoring for treatment 
response, side-eﬀ   ects, and drug adherence is done 
clinically, and routine laboratory monitoring is only done 
at a few central hospitals and externally supported sites. 
There are two alternative ﬁ  rst-line regimens for serious 
side-eﬀ  ects of ART drugs, and two second-line regimens 
for ART drug failure in adults and children. Second-line 
therapy is initiated at central and major district hospitals, 
based on specialist assessment that can include 
measurement of plasma HIV RNA. After successful 
switching, patients might be referred back to their 
peripheral ART sites with supplies of second-line drugs. 
This policy theoretically gives all patients access to second-
line ART while avoiding inappropriate regimen changes. 
Guidelines for the diagnosis of ART failure in Malawi 
are shown in the panel.
23 These guidelines diﬀ  er somewhat 
Number of ART clinics in the 
public and private sector
Number of patients 
registered for ART*
December, 2003 9 3000†
December, 2004 24 13 183
December, 2005 83 38 817
December, 2006 141 85 168
December, 2007 163 146 856
December, 2008 221 223 437
ART=antiretroviral therapy. *These data are the reported national numbers and 
include patients who have been transferred between clinics; such transferred 
patients are thus counted twice (ie, by December, 2008, 27 069 patients had been 
transferred between clinics, meaning that 196 368 patients had newly started 
ART). †Estimate. Data obtained from the Department of HIV and AIDS, Malawi 
Ministry of Health.
3
Table 1: Scale-up of antiretroviral therapy in Malawi
UK Malawi
Population 60 000 000 13 000 000
Gross domestic product per head (US$) 25 000 170
Health expenditure per head (US$) 3000 15
Physicians (n) 135 000 270
Nurses (n) 700 000 7300
People living with HIV (n) 70 000 950 000
Patients alive on ART (n) 36 000 142 000
Numbers are rounded down. ART=antiretroviral therapy.
Table 2: Economic and health-care diﬀ  erences between UK and Malawi 62  www.thelancet.com/infection   Vol 10   January 2010
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from the WHO recommendations, which also include the 
development of new WHO clinical stage 3 diseases such 
as pulmonary tuberculosis and severe bacterial infections.
24 
Although these guidelines seem straightforward, their 
implementation in the ﬁ  eld is fraught with diﬃ   culty. 
Diﬃ   culties in diagnosing therapy failure and 
initiating second-line ART
Patients on ﬁ  rst-line ART, whether healthy or sick, might 
have diﬃ   culty accessing ART clinics because of distance 
and high costs associated with transport.
25,26 In many rural 
settings, patients might also choose not to present to 
medical clinics, frustrated by unavailability of essential 
medicines and coupled with a strong belief in traditional 
medicine.
27 
ART clinics are usually busy and understaﬀ  ed, 
particularly in district government hospitals, many of 
which are run by only one or two nurses. In these 
circumstances, thorough clinical assessment is often 
impossible and new clinical conditions might be missed. 
Clinical assessment can also be misleading: WHO clinical 
stage 4 diseases such as extrapulmonary tuberculosis and 
Kaposi’s sarcoma can develop despite successful ART and 
a satisfactory CD4-cell count response.
28,29 Clinical 
indicators also have poor speciﬁ  city, a problem worsened 
by symptoms of drug toxicity that can easily be confused 
with those of opportunistic infections. For example, 
distinguishing between lactic acidosis (a long-term adverse 
eﬀ  ect of stavudine) and the development of Pneumocystis 
jirovecii  pneumonia can be diﬃ     cult in the absence of 
laboratory investigations. Immune reconstitution 
inﬂ  ammatory syndromes present early in the course of 
ART,
30 and should not cause confusion with diseases 
presenting later as a result of ART failure. 
Most patients starting ART in Malawi have no baseline 
CD4-cell count that would allow detection of a subsequent 
decline.
3 CD4-cell count monitoring is only available at a 
few centres of excellence, and where CD4-cell counts are 
done, there are sometimes concerns over quality 
assurance. 
Discordant responses of CD4-cell counts and virological 
load are well known in resource-limited settings.
31 In 
South Africa, the positive predictive values of WHO clinical 
and CD4-cell count criteria in diagnosing virological failure 
were 13% and 38%, respectively, meaning that a large 
proportion of patients would be incorrectly diagnosed as 
having treatment failure and switched unnecessarily to 
second-line therapy.
32 Poor predictive values of CD4-cell 





35,36 Whereas some studies 
have found that the negative predictive value of CD4-cell 
counts is high,
37 this ﬁ  nding is not consistent: for example, 
in a relatively well-resourced Médecins Sans Frontières 
programme in Mozambique, only 33% of patients with 
plasma HIV RNA concentrations of at least 
1000 copies per mL manifested clinical or immunological 
signs suggestive of virological failure.
38  
In Malawi, the second-line regimen is currently not 
stocked at peripheral ART clinics for reasons of cost and 
lack of expertise in its use. Adults on second-line ART take 
one tablet of zidovudine and lamivudine twice daily, one 
tablet of tenofovir once daily, and two tablets of ritonavir-
boosted lopinavir twice daily. This regimen costs ten times 
as much as ﬁ  rst-line ART and increases the pill burden 
substantially. The systems of referral for expert assessment 
and initiation of second-line treatment at central or major 
district hospitals and back-referral with supplies of second-
line drugs are expensive for patients and demanding for 
health workers. Lack of appropriate guidance to patients 
for the more complicated regimen might lead to 
suboptimum adherence on second-line ART. However, in 
well-resourced clinics, such as those run by Médecins Sans 
Frontières, a switch to protease-inhibitor-based second-
line therapy in situations in which patients have truly 
failed ﬁ  rst-line ART is associated with excellent clinical 
and immunological outcomes.
39
Given the diﬃ   culties in diagnosis and management, 
what does in fact happen to patients who fail ﬁ  rst-line 
ART in large national programmes? The honest answer 
is that we do not know, although many patients probably 
develop HIV-related disease and die. Such cases would 
be accounted for as “lost to follow-up” or “died” in routine 
monitoring data. By Dec 31, 2008, 23 699 patients (12%) 
of the 196 368 new patients who initiated ART in Malawi 
were known to have died. Although nearly two-thirds of 
deaths happened within 3 months after starting ART, an 
increasing proportion of patients are dying later.
3 A 
further 24  409 patients (12%) were classiﬁ  ed as “lost to 
follow-up”, meaning that they have not returned to clinic 
for 3 months or longer. Operational research has shown 
that 50% of patients lost to follow-up have died,
40 although 
more work needs to be done to elucidate when in the 
course of therapy this takes place. Although much of 
Panel: Diagnosis of antiretroviral therapy (ART) failure in 
Malawi—version 3 of the guidelines
ART failure is deﬁ  ned when conditions A+B+C have been 
fulﬁ  lled:
(A) On ART for at least 12 months and adhering to therapy.
(B) Fulﬁ  l at least one of the following criteria:
(1) the development of a new WHO clinical stage 4 disease 
or feature,
(2) CD4-cell count/percentage that has declined to 
pretreatment values or less,
(3) CD4-cell count/percentage that has declined to below 
50% of peak value on ART.
(C) CD4-cell count below 200×10⁶ cells per L.
CD4-cell count needs to be repeated after 1 month, and the 
patient is referred only if the result supports the earlier CD4-
cell count. The decision to change to a second-line regimen is 
made in consultation with a specialist or experienced clinician 
at one of the dedicated clinics, with access to viral-load tests.
23www.thelancet.com/infection   Vol 10   January 2010  63
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current research focuses on establishing the reasons for 
early ART mortality,
41 better quantitative estimates are 
needed for late ART deaths and the causes, which are 
likely to be long-term ART toxic eﬀ  ects, such as lactic 
acidosis, and development of serious stage 4 disease and 
ART failure. 
Improving diagnosis and management
Laboratory monitoring in resource-poor settings
The Development of Antiretroviral Therapy in Africa 
(DART) trial compared 5-year outcomes in patients in 
Uganda and Zimbabwe who were randomly assigned to 
clinical and laboratory monitoring (for side-eﬀ  ects and 
CD4-cell counts) versus clinical monitoring alone. 
Diﬀ  erences in mortality and WHO stage 4 event-free 
survival were small,
42 supporting ﬁ  ndings from a previous 
mathematical model suggesting that the addition of 
laboratory monitoring for side-eﬀ   ects and CD4-cell 
counts provides little added beneﬁ   t compared with 
clinical monitoring alone.
43 However, these ﬁ  ndings do 
not take into account the poor performance of current 
clinical monitoring found in routine practice. The DART 
study also suggested that improved laboratory monitoring 
has a deﬁ  nite role in guiding the switching of therapy 
from the second year on ART. A theoretical ART failure 
model has been described that incorporates treatment 
and adherence history, clinical events, and basic 
laboratory results.
44 However, development of a composite 
diagnostic tool for ART failure that has good test 
characteristics, yet is simple enough for use in busy, 
undermanned clinics will be a huge challenge. A diﬀ  erent 
approach is urgently needed. 
A point-of-care viral-load test
The rapid POC HIV test has revolutionised counselling 
and testing by replacing the cumbersome and slow 
ELISA method. Development of a rapid POC viral-load 
test will, we hope, provide a similar revolution in ART 
management. Field-friendly methods for specimen 
collection for HIV-1 viral-load measurement in Africa 
through the use of dried blood spots on ﬁ  lter paper have 
already been successfully tested in Zambia and rural 
Tanzania.
45,46 Similarly, substantial progress is being made 
in the development of a rapid POC test for CD4-cell 
count, speciﬁ   cally designed for use in resource-poor 
settings. Such a test is simple to use, relies on ﬁ  nger-
prick blood sampling, and is not dependent on 
instrumentation or electronics. It also has the potential 
to improve access to ART at an earlier stage than is the 
case at present in sub-Saharan Africa (unpublished). To 
be applicable in peripheral clinics and remote health 
centres in sub-Saharan Africa, a POC viral-load test 
would need to have the same characteristics as those 
deﬁ  ned for a POC CD4-cell count test: simple to use and 
easy to read; independent of instrumentation or 
electronics; robust and able to withstand increased 
ambient temperatures without cold-chain shipment or 
storage; long shelf-life (longer than 12 months); and 
inexpensive (no more that $2 per test to manufacture). 
One contentious issue will be the HIV RNA 
concentration at which virological failure is deemed to 
occur. We still need to deﬁ  ne the viral-load concentrations 
at which immunological and clinical deterioration 
happen, and accumulation of important resistance 
mutations can be expected (ie, those that compromise 
outcome of standard second-line ART regimens). In 
Cameroon, 50% of patients with plasma HIV RNA 
concentrations above 1000 copies per mL harboured 
drug-resistant strains compared with 70% of patients 
with above 10  000 HIV RNA copies per mL, the latter 
threshold being the present WHO recommendation for a 
switch to second-line ART.
13 Waiting until a threshold of 
10 000 copies per mL has been reached might mean that 
most patients already have multiple, clinically important, 
drug-resistant mutations. However, whereas a plasma 
HIV RNA concentration of 10  000 copies per mL might 
be detectable by traditional immunoassays and 
technologies such as HIV strip tests, a plasma HIV RNA 
below 1000 copies per mL might not, which would 
increase the complexity of the POC test, its cost, and 
likelihood of successful development.  
Virological testing has also been shown to be a useful 
operational support tool for improving adherence and 
patient support.
14,47 Thus, widespread availability of a 
viral-load test might help to conserve ﬁ  rst-line regimens 
and might have a preventive dimension in ART failure. 
In the development of a POC viral-load test, clear 
guidance will be needed on the viral-load threshold 
around which action is taken, the frequency of testing, 
when to repeat the test if the viral load is high, and when 
to switch therapies. 
A simpler second-line ART regimen
Rolling out ART to primary health-care level will inevitably 
require task shifting to cope with the ever growing 
numbers of patients being initiated and maintained on 
life-long treatment.
48 Therefore, second-line ART must be 
made as simple as possible. Given the high genetic barrier 
to resistance, the use of ritonavir-boosted lopinavir, 
atazanavir, or darunavir is being considered as 
monotherapy.
49–52 The AIDS Clinical Trials Group 
(sponsored by the US National Institutes of Health) is 
currently doing a clinical trial on ritonavir-boosted 
lopinavir in patients on failing non-NRTI regimens 
(ClinicalTrials.gov reference NCT00357552). The UK 
Medical Research Council is planning the EARNEST 
(Eastern and Southern African Network for Evaluation of 
Second-Line Therapy) clinical trial, which will randomise 
patients to receive a boosted protease inhibitor and two 
NRTIs (as per current WHO guidelines), boosted 
protease-inhibitor monotherapy, or boosted protease 
inhibitor plus the integrase inhibitor raltegravir. 
Boosted protease-inhibitor monotherapy for second-
line ART is attractive for the following reasons: it is 64  www.thelancet.com/infection   Vol 10   January 2010
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independent of resistance to ﬁ  rst-line agents; the non-
overlapping resistance proﬁ  le with ﬁ  rst-line drugs makes 
resistance testing redundant; toxic eﬀ  ects due to NRTIs 
are eliminated; drug costs are minimised; and in busy 
clinics, there is less room for error by both health-care 
provider and patient. In most patients who fail ﬁ  rst-line 
therapy in Africa, NRTIs in second-line treatment might 
be expected to have very little activity due to the presence 
of extensive NRTI resistance. Currently ritonavir-boosted 
lopinavir is the protease inhibitor of choice in resource-
limited settings because of its heat-stable formulation 
and substantial experience with its use. Ritonavir-boosted 
atazanavir is attractive because of once daily dosing and 
safety: it has a more favourable lipid proﬁ  le and causes 
less lipodystrophy, although it is commonly associated 
with hyperbili rubinaemia.
53 However, although atazanavir 
is available in heat-stable tablet form, it must be boosted 
with low-dose ritonavir, which is still only available in 
soft gel capsules that are sensitive to heat. 
For patients in whom tuberculosis heralds the failure 
of ﬁ  rst-line ART, there will be a need to ﬁ  nd solutions to 
the use of protease inhibitors with antituberculosis 
treatment. The ideal option would be for rifabutin to 
replace rifampicin, but the former drug is still expensive 
and rarely available in resource-limited settings. The 
other, less desirable and complex, option is to continue 
with rifampicin but increase protease-inhibitor boosting, 
which could compromise safety.
24
Conclusions
ART scale-up in sub-Saharan Africa is a relatively new 
phenomenon, but one that is already changing the 
landscape of health-care provision. Life-long chronic care 
is required for the eﬀ  ective and safe administration of 
therapy to the millions of African patients who will 
eventually need it. Complicated ART delivery models will 
not work,
54 and simple, robust systems are needed to 
protect health services from being overwhelmed. 
First-line ART must be protected for as long as possible 
by paying due attention to issues of adherence, 
consideration of less-toxic yet simple-to-take regimens, 
and an earlier start of therapy, the latter having a potential 
survival advantage and associated with a lower risk of 
drug-resistance mutations.
55–57 The current clinical and 
immunological criteria to diagnose ART failure in Africa 
are unreliable, with many patients who fail not being 
detected and others being prematurely switched, at great 
cost to individuals and to programmes.
58 We believe that 
a POC viral-load test has the potential to dramatically 
improve the management of patients, although 
operational research will be needed to determine the 
thresholds required and the frequency of testing. If more 
patients are identiﬁ  ed with ART failure, an easy-to-use 
and relatively inexpensive second-line therapy has to be 
available. Boosted protease-inhibitor monotherapy is an 
attractive option,
59 and needs to be assessed for both 
feasibility and eﬃ   cacy in the ﬁ  eld. 
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